Regen BioPharma Inc (RGBP)

[buckiii2]

According to the company, initial indications for NR2F6 activators include rheumatoid arthritis, inflammatory bowel disease and psoriasis, while indications for blockers include bladder cancer, myelodysplastic syndrome (a group of disorders caused by blood cells not formed or not working properly), and lung cancer.

Additional potential indications are solid tumors, acute leukemia and chronic graft-versus-host disease, which consists in the attack of the host’s cells by transplanted stem cells.

https://lupusnewstoday.com/2018/08/31/molecules-targeting-immune-protein-nr2f6-eyed-as-therapy-lupus/